GO:0038196 type III interferon-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038196 describes the signaling cascade triggered when type III interferons (interferon lambda, IFNL) bind their receptor on target cells, culminating in transcriptional regulation of antiviral genes.
• Interferon lambda is the only known type III interferon and signals through a heterodimeric receptor composed of IFNLR1 and IL10RB.
• Type III interferon signaling is critical for controlling viral infections such as yellow fever virus in vivo, as shown by Douam et al. (2017).
• Viruses including Zika virus and Epstein-Barr virus have evolved mechanisms to suppress interferon-mediated signaling, highlighting its importance in host defense.
• The pathway is regulated by metabolic cues and can be modulated by long non-coding RNAs, offering new research avenues.
• CRISPR-based models (knockout, knock-in, overexpression) are essential tools to dissect the causal roles of genes in this pathway.
Description
The type III interferon-mediated signaling pathway (GO:0038196) is a biological process initiated by the binding of type III interferons, specifically interferon lambda (IFNL), to their cell surface receptor. This pathway is a key component of innate antiviral immunity, leading to the regulation of downstream cellular processes such as transcription of interferon-stimulated genes (ISGs). Unlike type I interferons, type III interferons signal through a distinct receptor complex composed of IFNLR1 and IL10RB, which is expressed primarily on epithelial cells, providing tissue-specific antiviral protection. Understanding this pathway is crucial for researchers studying host-pathogen interactions, as many viruses have evolved strategies to evade or suppress interferon signaling. Moreover, the pathway intersects with metabolic regulation and non-coding RNA networks, making it a rich area for therapeutic intervention.
type III interferon-mediated signaling pathway At A Glance
| GO ID | GO:0038196 |
|---|---|
| GO term | type III interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | interferon lambda signaling pathway; type III interferon-activated signaling pathway; type III interferon signaling pathway |
| Major function | Antiviral defense and regulation of gene expression in response to type III interferons |
| Key receptor | Heterodimer of IFNLR1 and IL10RB |
| Primary ligand | Interferon lambda (IFNL) |
| Downstream effect | Activation of JAK-STAT signaling and transcription of interferon-stimulated genes |
What Is GO:0038196?
According to the Gene Ontology, GO:0038196 is defined as the series of molecular signals initiated by type III interferon binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Interferon lambda is the only member of the type III interferon family identified so far. This process encompasses receptor activation, intracellular signal transduction, and the eventual modulation of gene expression to establish an antiviral state.
Why Is type III interferon-mediated signaling pathway Important in Cell Biology?
The type III interferon-mediated signaling pathway is essential for host defense against viral infections, particularly at mucosal surfaces where IFNLR1 expression is high. Its unique receptor distribution allows for targeted antiviral responses with reduced systemic inflammation compared to type I interferons. Dysregulation of this pathway has been implicated in viral pathogenesis, as viruses such as Zika and Epstein-Barr virus can inhibit interferon signaling to evade immune clearance. Furthermore, the pathway is influenced by metabolic states and gut microbiota, linking it to broader physiological contexts including cancer and respiratory diseases. Therefore, studying GO:0038196 provides insights into fundamental immunology and potential therapeutic targets.
• Critical for controlling live attenuated yellow fever virus infection in vivo.
• Targeted by viral evasion mechanisms, e.g., Zika virus inhibits type I interferon production and downstream signaling.
• Regulated by nucleic acid sensors and innate immune signaling pathways.
• Influenced by metabolic regulation, affecting antiviral immunity.
• Suppressed by Epstein-Barr virus tegument protein BGLF2 through SHP1 recruitment and STAT2 degradation.
• Plays a role in influenza A virus infection and host innate immunity.
• Modulated by long non-coding RNAs in respiratory tract antiviral responses.
• Linked to gut microbiota regulation of programmed cell death in colorectal cancer.
What Happens During type III interferon-mediated signaling pathway?
Ligand Binding and Receptor Activation
In simple terms: Interferon lambda binds to its receptor on the cell surface, like a key fitting a lock.
The pathway begins when type III interferon (IFNL) binds to the heterodimeric receptor composed of IFNLR1 and IL10RB. This binding induces conformational changes that activate receptor-associated Janus kinases (JAKs), leading to phosphorylation of the receptor intracellular domains. This step is critical for initiating downstream signaling and is conserved across type III interferon responses.
JAK-STAT Signal Transduction
In simple terms: Activated JAKs phosphorylate STAT proteins, which then move to the nucleus to turn on antiviral genes.
Upon receptor activation, JAK1 and TYK2 phosphorylate STAT1 and STAT2, which then form a heterotrimer with IRF9, known as ISGF3. This complex translocates to the nucleus and binds to interferon-stimulated response elements (ISREs) in the promoters of interferon-stimulated genes (ISGs), initiating transcription. This canonical JAK-STAT cascade is the central mechanism of type III interferon signaling.
Regulation of Downstream Cellular Processes
In simple terms: The signal ultimately changes which genes are turned on or off, helping the cell fight viruses.
The transcriptional program induced by type III interferon signaling leads to the expression of numerous antiviral effectors that inhibit viral replication, modulate cell growth, and regulate immune responses. Additionally, the pathway can crosstalk with other signaling cascades, such as those mediated by nucleic acid sensors, to fine-tune the innate immune response.
Viral Evasion and Modulation
In simple terms: Some viruses have ways to block or weaken this signaling to survive.
Viruses have evolved diverse strategies to antagonize type III interferon signaling. For example, Zika virus inhibits type I interferon production and downstream signaling, which may also affect type III responses. Epstein-Barr virus protein BGLF2 recruits SHP1 phosphatase to promote STAT2 degradation, thereby suppressing JAK-STAT signaling. These evasion mechanisms highlight the evolutionary arms race between host and pathogens.
Key Genes Involved in GO:0038196 type III interferon-mediated signaling pathway
The following genes are key components or regulators of the type III interferon-mediated signaling pathway, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNL1 | Type III interferon ligand (IFN-lambda1) | Initiates signaling by binding to IFNLR1/IL10RB |
| IFNL2 | Type III interferon ligand (IFN-lambda2) | Alternative ligand with similar function |
| IFNL3 | Type III interferon ligand (IFN-lambda3) | Associated with antiviral responses |
| IFNL4 | Type III interferon ligand (IFN-lambda4) | May modulate signaling |
| IFNLR1 | Receptor subunit specific for type III IFN | Essential for ligand binding and signal initiation |
| IL10RB | Shared receptor subunit | Required for functional receptor complex |
| JAK1 | Janus kinase | Phosphorylates STAT proteins upon receptor activation |
| TYK2 | Janus kinase | Phosphorylates STAT proteins upon receptor activation |
| STAT1 | Signal transducer and activator of transcription | Forms ISGF3 complex to activate ISGs |
| STAT2 | Signal transducer and activator of transcription | Forms ISGF3 complex; targeted for degradation by EBV BGLF2 |
| IRF9 | Interferon regulatory factor | Part of ISGF3 complex |
| SHP1 | Protein tyrosine phosphatase | Recruited by EBV BGLF2 to inhibit JAK-STAT signaling |
| BGLF2 | Epstein-Barr virus tegument protein | Suppresses JAK-STAT signaling via SHP1 and STAT2 degradation |
| ISG15 | Interferon-stimulated gene | Antiviral effector induced by signaling |
| MX1 | Interferon-stimulated gene | Antiviral effector induced by signaling |
| OAS1 | Interferon-stimulated gene | Antiviral effector induced by signaling |
| PKR | Interferon-stimulated gene | Antiviral effector induced by signaling |
How Is type III interferon-mediated signaling pathway Regulated?
The type III interferon-mediated signaling pathway is subject to multiple layers of regulation. Metabolic cues can influence interferon-mediated innate antiviral immunity, as reviewed by Zhong et al. (2025). Long non-coding RNAs have been shown to govern antiviral immune responses through interferon-mediated mechanisms in the respiratory tract. Additionally, nucleic acid sensors regulate innate interferon-mediated responses during viral infection, impacting the strength and duration of signaling. Viral proteins such as EBV BGLF2 can directly inhibit the pathway by recruiting phosphatases and promoting STAT2 degradation.
type III interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNL | Yellow fever virus infection | Knockout mouse or cell line |
| STAT2 | Epstein-Barr virus infection | Knockout or knockdown cells |
| IFNLR1 | Viral infections | Knockout mice |
| IL10RB | Viral infections | Knockout cells |
| ISG15 | Antiviral immunity | Overexpression or knockout cells |
Viral Infections
Type III interferon signaling is critical for controlling viral infections. Douam et al. (2017) demonstrated that type III interferon-mediated signaling is essential for controlling live attenuated yellow fever virus infection in vivo. Zika virus inhibits type I interferon production and downstream signaling, potentially interfering with type III responses as well. Influenza A virus infection also involves interferon-mediated host innate immunity.
Cancer and Microbiota
The gut microbiota regulates interferon-mediated programmed cell death in colorectal cancer, linking type III interferon signaling to cancer biology. This suggests that the pathway may influence tumor progression and response to therapy.
Respiratory Tract Diseases
Long non-coding RNAs can govern antiviral immune responses through interferon-mediated mechanisms in the respiratory tract, implicating type III interferon signaling in respiratory viral infections and chronic lung diseases.
From type III interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IFNLR1 mediate type III interferon signaling? | IFNLR1 knockout cell line |
| What is the role of STAT2 in antiviral defense? | STAT2 knockout or point-mutation cells |
| How does EBV BGLF2 suppress JAK-STAT signaling? | Knock-in of BGLF2 or overexpression |
| Can type III interferon inhibit yellow fever virus? | Knockout mouse models |
| What genes are induced by type III interferon? | RNA-seq after IFN-lambda treatment |
| Does a SNP in IFNL3 affect signaling? | Point-mutation knock-in cells |
How to Study the type III interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify ISGs induced by IFN-lambda |
| Proteomics | Protein abundance and modifications | Quantify JAK-STAT activation |
| CRISPR knockout screening | Gene essentiality for signaling | Discover host factors |
| Phospho-STAT Western blot | STAT phosphorylation status | Monitor pathway activation |
| Luciferase reporter assay | ISRE-driven transcription | Measure signaling activity |
| Immunofluorescence | STAT nuclear translocation | Visualize pathway activation |
| Co-immunoprecipitation | Protein-protein interactions | Study receptor complex assembly |
Transcriptomic Analysis
RNA sequencing (RNA-seq) is widely used to identify interferon-stimulated genes induced by type III interferon signaling. This method provides a global view of transcriptional changes and can reveal novel effectors and regulatory networks.
Proteomic and Phosphoproteomic Approaches
Mass spectrometry-based proteomics can quantify protein abundance and phosphorylation events in the JAK-STAT pathway, helping to dissect signaling dynamics and identify post-translational modifications.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that are essential for type III interferon-mediated signaling or that mediate viral evasion. This unbiased approach has been used to uncover host factors required for interferon responses.
Imaging and Reporter Assays
Fluorescence microscopy and luciferase reporter assays can visualize STAT nuclear translocation and ISRE-driven transcription, providing spatial and kinetic information about the pathway.
How CRISPR Can Be Used to Study GO:0038196 type III interferon-mediated signaling pathway
Knockout
CRISPR knockout of genes such as IFNLR1, IL10RB, JAK1, TYK2, STAT1, or STAT2 can abolish type III interferon signaling, providing definitive evidence of their essential roles. Douam et al. (2017) used knockout models to demonstrate the critical role of type III interferon signaling in controlling yellow fever virus.
Point Mutation
Introducing point mutations in signaling components (e.g., phosphorylation sites in STAT1 or STAT2) can dissect the functional relevance of specific residues. This approach helps to understand how post-translational modifications regulate the pathway.
Knock-in
Knock-in of tagged versions of pathway proteins (e.g., GFP-STAT1) allows real-time tracking of protein localization and interactions. Additionally, knock-in of viral evasion proteins like EBV BGLF2 can model virus-host interactions.
Overexpression
Overexpression of type III interferons or their receptor components can amplify signaling and enhance antiviral responses. This is useful for studying gain-of-function effects and for therapeutic applications.
How EDITGENE Supports type III interferon-mediated signaling pathway Research
Researchers studying type III interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in antiviral defense, immune regulation, or disease pathogenesis. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models, enabling functional validation of genes in this pathway.
Contact EDITGENE today to design your custom CRISPR model for type III interferon-mediated signaling pathway research.
Frequently Asked Questions About type III interferon-mediated signaling pathway
What is the type III interferon-mediated signaling pathway?
It is the series of molecular signals initiated by type III interferon (interferon lambda) binding to its receptor, leading to regulation of downstream cellular processes such as transcription.
What genes are involved in type III interferon-mediated signaling pathway?
Key genes include IFNL1, IFNL2, IFNL3, IFNL4, IFNLR1, IL10RB, JAK1, TYK2, STAT1, STAT2, and IRF9.
What is the GO ID for type III interferon-mediated signaling pathway?
The GO ID is GO:0038196.
How does type III interferon signaling differ from type I interferon signaling?
Type III interferons bind a distinct receptor (IFNLR1/IL10RB) and are primarily expressed in epithelial cells, whereas type I interferons bind IFNAR1/IFNAR2 and act more systemically.
Which viruses are controlled by type III interferon signaling?
Type III interferon signaling is critical for controlling yellow fever virus, and may also play roles in Zika virus and influenza A virus infections.
How do viruses evade type III interferon signaling?
Viruses such as Epstein-Barr virus express proteins like BGLF2 that recruit SHP1 phosphatase and promote STAT2 degradation to suppress JAK-STAT signaling.
What experimental models are used to study type III interferon signaling?
Common models include CRISPR knockout cell lines, knockout mice, and overexpression systems for pathway components.
What are the downstream effects of type III interferon signaling?
It induces transcription of interferon-stimulated genes (ISGs) that inhibit viral replication and modulate immune responses.
Is type III interferon signaling regulated by non-coding RNAs?
Yes, long non-coding RNAs can govern antiviral immune responses through interferon-mediated mechanisms in the respiratory tract.
How can CRISPR be used to study type III interferon signaling?
CRISPR can create knockouts, point mutations, knock-ins, and overexpression models to dissect gene function in the pathway.
Conclusion
The type III interferon-mediated signaling pathway (GO:0038196) is a vital component of innate antiviral immunity, with unique receptor specificity and tissue distribution. Its role in controlling viral infections and its modulation by viral evasion mechanisms make it a compelling research focus. Advances in CRISPR technology and omics approaches continue to unravel the complexities of this pathway, offering potential for novel antiviral therapies.
References
- 1. Douam F et al.. 2017. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.. mBio 8(4) PMID: 28811340
- 2. Kumar A et al.. 2016. Zika virus inhibits type-I interferon production and downstream signaling.. EMBO Rep 17(12):1766-1775 PMID: 27797853
- 3. Takaoka A et al.. 2019. Regulation of signaling mediated by nucleic acid sensors for innate interferon-mediated responses during viral infection.. Int Immunol 31(8):477-488 PMID: 30985869
- 4. Zhong T et al.. 2025. Metabolic regulation of interferon-mediated innate antiviral immunity.. Front Immunol 16:1680688 PMID: 41132680
- 5. Jangra S et al.. 2021. Suppression of JAK-STAT Signaling by Epstein-Barr Virus Tegument Protein BGLF2 through Recruitment of SHP1 Phosphatase and Promotion of STAT2 Degradation.. J Virol 95(20):e0102721 PMID: 34319780
- 6. Chen C et al.. 2015. [Mechanisms underlying interferon-mediated host innate immunity during influenza A virus infection].. Sheng Wu Gong Cheng Xue Bao 31(12):1671-81 PMID: 27093830
- 7. Lozhkov A et al.. 2026. Long Non-Coding RNAs Can Govern the Antiviral Immune Response Through Interferon-Mediated Mechanisms in Respiratory Tract.. Viruses 18(2) PMID: 41754574
- 8. Yao Q et al.. 2025. Role and mechanism of gut microbiota in regulating interferon-mediated programmed cell death in colorectal cancer.. Front Immunol 16:1724908 PMID: 41601698
